[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638915":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":14,"locations":20,"responsibleParty":42,"collaborators":44,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":67,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Universidade Nova de Lisboa","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Retrospective Cohort I: 70 patients (35 patients for group 1 and 35 patients for group 2)",null,"Group 1: patients newly diagnosed with early-stage LUAD, STAS negative Group 2: patients newly diagnosed with early-stage LUAD, STAS positive",{"label":13,"type":10,"description":11,"interventionNames":10},"Prospective Cohort II: 70 patients (35 patients for group 1 and 35 patients for group 2)",[15],{"name":16,"role":17,"phone":18,"phoneExt":10,"email":19},"Bárbara da Silva Mendes, PhD","CONTACT","+351 218 803 000","barbara.mendes@nms.unl.pt",[21,32],{"facility":22,"status":10,"city":23,"state":10,"zip":10,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":10},"NMS Research | Cancer Nanomedicine - João Conde's Lab","Lisbon","Portugal","PT",{"type":27,"coordinates":28},"Point",[29,30],-9.1498,38.72509,{"lat":30,"lon":29},{"facility":33,"status":10,"city":23,"state":10,"zip":10,"country":24,"countryCode":25,"cosmosGeoPoint":34,"geoPoint":36,"contacts":37},"Unidade Local de Saúde de São José",{"type":27,"coordinates":35},[29,30],{"lat":30,"lon":29},[38],{"name":39,"role":17,"phone":40,"phoneExt":10,"email":41},"Paulo Calvinho, MD","+3512138841988","paulo.calvinho@nms.unl.pt",{"type":43,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[45],{"name":33,"class":46},"INDIV","100638915","clinical-study-to-identify-biomarkers-for-tumor-spread-through-air-spaces-status-100638915",false,"NCT07630246","CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS","UNCOVERING THE GENETIC LANDSCAPE OF LUNG ADENOCARCINOMA: A CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUS","PAIR-LUNG","Inclusion Criteria:\n\n* Patients older than 18 years old\n* Active early LUAD diagnosis according to the American Joint Committee on Cancer\n* Signed informed consent or previous consent given for future research\n\nExclusion Criteria:\n\n* History of inflammatory bowel disease and autoimmune diseases\n* History of hepatic disease (including history of alcoholic or viral hepatitis)\n* LUAD patients with other active malignancy(ies)\n* Previous treatment for LUAD\n* Incapability of understanding the study and\u002For providing consent\n* Signed informed consent unavailable","ALL","18 Years",{"count":58,"type":59},140,"ESTIMATED","1 Year","OBSERVATIONAL","Lung cancer remains a significant challenge in oncology, with poor prognosis for patients, especially those with advanced-stage disease. The phenomenon of tumor spread through air spaces (STAS) in pulmonary cancer has garnered attention for its association with aggressive tumor behavior and adverse clinical outcomes. Spread through air spaces identification has been highly debatable on scientific community as an important prognostic feature for distant and locoregional recurrence and as a key player in the differential diagnosis and selection of the appropriate treatment. The aim of this study is to unravel the complexities of STAS-positive lung adenocarcinoma (LUAD) diagnosis and treatment options. For that, we intend to (1) isolate primary lung cancer tissues from early-stages lung adenocarcinoma to fabricate organoid in vitro models and (2) evaluate the microRNA (miRNA) profile of tumor and healthy tissue samples. This is a Hybrid (prospective and retrospective) observational clinical study with a nested translational study.",[64],"Lung Adenocarcinoma",[66],"Pulmonary cancer, Lung, Tumor spread through air spaces","NOT_YET_RECRUITING","2026-06-01",{"date":70,"type":71},"2026-06-05","ACTUAL",{"date":68,"type":59},{"date":74,"type":59},"2029-06-30",{"name":5,"class":6},2]